QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.106.023762v1 70/2/656    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jakubík, J. Articles by Dolezal, V. Search for Related Content PubMed PubMed Citation Articles by Jakubík, J. Articles by Dolezal, V.

Differences in Kinetics of Xanomeline Binding and Selectivity of Activation of G Proteins at M₁ and M₂ Muscarinic Acetylcholine Receptors

Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic (J.J., V.D.); and Division of Neuroscience Research in Psychiatry, University of Minnesota Medical School, Minneapolis, Minnesota (E.E.E.-F.)

Xanomeline is a functionally selective M₁/M₄ muscarinic acetylcholine receptor agonist that nevertheless binds with high affinity to all five subtypes of muscarinic receptors. A novel mode of interaction of this ligand with the muscarinic M₁ receptors characterized by persistent binding and receptor activation after extensive washout has been shown previously. In the present study, using human M₁ and M₂ receptors expressed in Chinese hamster ovary cells and [³H]N-methylscopolamine as a tracer, we show that persistent binding of xanomeline also occurs at the M₂ receptor with similar affinity as at the M₁ receptor (K_I = 294 and 296 nM, respectively). However, kinetics of formation of xanomeline wash-resistant binding to M₂ receptors was markedly slower than to M₁ receptors. Xanomeline was a potent fast-acting full agonist in stimulating guanosine 5'-O-(3-[³⁵S]thio)triphosphate binding at M₁ receptors, whereas at M₂ receptors it behaved as a potent partial agonist (40% of carbachol maximal response) only upon preincubation for 1 h. Development of xanomeline agonistic effects at the M₂ receptor was slower than its ability to attenuate carbachol responses. We also demonstrate that xanomeline discriminates better between G protein subtypes at M₁ than at M₂ receptors. Our data support the notion that xanomeline interacts with multiple sites on the muscarinic receptor, resulting in divergent conformations that exhibit differential effects on ligand binding and receptor activation. These conformations are both time- and concentration-dependent and vary between the M₁ and the M₂ receptor.

Received for publication February 23, 2006.

Accepted for publication May 4, 2006.

Address correspondence to: Dr. J. Jakubík, Department of Neurochemistry, Institute of Physiology CAS, Vídeská 1083, 14220 Prague, Czech Republic. E-mail: jakubik{at}biomed.cas.cz

This article has been cited by other articles:

				K. C. De Lorme, M. K.O. Grant, M. J. Noetzel, S. B. Polson, and E. E. El-Fakahany Long-Term Changes in the Muscarinic M1 Receptor Induced by Instantaneous Formation of Wash-Resistant Xanomeline-Receptor Complex J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 868 - 876. [Abstract] [Full Text] [PDF]

				E. Machova, J. Jakubik, E. E. El-Fakahany, and V. Dolezal Wash-Resistantly Bound Xanomeline Inhibits Acetylcholine Release by Persistent Activation of Presynaptic M2 and M4 Muscarinic Receptors in Rat Brain J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 316 - 323. [Abstract] [Full Text] [PDF]

				P. Michal, E. E. El-Fakahany, and V. Dolezal Muscarinic M2 Receptors Directly Activate Gq/11 and Gs G-Proteins J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 607 - 614. [Abstract] [Full Text] [PDF]